August 19, 2020

In re: Seroquel XR (Extended Release Quetiapine Fumarate) Litigation All End-Payor Class Actions

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. November 13, 2020

    3 Firms Score End-Payor Co-Lead Role In Seroquel XR Cases

    A Delaware federal judge on Friday tapped three firms — Grant & Eisenhofer PA, Cohen Milstein Sellers & Toll PLLC and Shepherd Finkelman Miller & Shah LLP — to lead the proposed end-payor class accusing AstraZeneca of paying off generic-drug makers to protect its brand antipsychotic drug Seroquel XR.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS